Results of interferon alpha-2a therapy in patients with Behcet's disease

Journal of Ocular Pharmacology and Therapeutics

Volumn 28, Issue 4, 2012, Pages 439-443

  Yalçindaǧ, F Nilüfer ^a   Uzun, Aslihan ^a  

^a ANKARA UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; AZATHIOPRINE; CYCLOSPORIN; INFLIXIMAB; PARACETAMOL; PREDNISONE;

ADULT; ARTHRITIS; ARTICLE; BEHCET DISEASE; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ERUPTION; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; HAIR LOSS; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; RELAPSE; REMISSION; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT RESPONSE; VISUAL ACUITY;

ADULT; BEHCET SYNDROME; DRUG RESISTANCE; EYE; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-ALPHA; LIGHT; MALE; MIDDLE AGED; OPTIC DISK; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; UVEITIS, ANTERIOR; VISION, OCULAR; VISUAL ACUITY; VISUAL PERCEPTION; YOUNG ADULT;

EID: 84864612321     PISSN: 10807683     EISSN: 15577732     Source Type: Journal    
DOI: 10.1089/jop.2011.0238     Document Type: Article

References (21)

1. Behcet, H. Über rezidiverende aphtöse durch ein virus verursachte Geschwüre am Mund, am Auge, und an den Genitalien. Dermatol. Wochenschr. 105:1152-1157, 1937.
2. International Study Group for Behcet's Disease. Criteria for diagnosis of Behcet's disease. Lancet 335:1078-1080, 1990.
3. Alpsoy, E., Durusoy, C., Yilmaz, E., et al. Interferon alfa-2a in the treatment of Behçet disease: A randomized placebocontrolled and double-blind study. Arch. Dermatol. 138:467-471, 2002.
4. Pipitone, N., Olivieri, I., Cantini, F., Triolo, G., Salvarani, C. New approaches in the treatment of Adamantiades-Behçet's disease. Curr. Opin. Rheumatol. 18:3-9, 2006.
5. Onal, S., Kazokoglu, H., Koc, A., et al. Long-term efficacy and safety of low-dose and dose-escalating interferon alfa-2a therapy in refractory Behçet uveitis. Arch. Ophthalmol. 129:288-294, 2011.
6. Krause, L., Altenburg, A., Pleyer, U., et al. Longterm visual prognosis of patients with ocular Adamantiades-Behçet's disease treated with interferon-alpha-2a. J. Rheumatol. 35: 896-903, 2008.
7. Deuter, C.M., Zierhut, M., Möhle, A., et al. Long-term remission after cessation of interferon-a treatment in patients with severe uveitis due to Behçet's disease. Arthritis Rheum. 62:2796-2805, 2010.
8. Cekmen, M., Evereklioglu, C., Er, H., et al. Vascular endothelial growth factor levels are increased and associated with disease activity in patients with Behcet's syndrome. Int. J. Dermatol. 42:870-875, 2003.
9. Ideguchi, H., Suda, A., Takeno, M., et al. Behcet disease: Evolution of clinical manifestations. Medicine (Baltimore) 90:125-132, 2011.
10. Hatemi, G., Silman, A., Bang, D., et al. EULAR recommendations fort he management of Behcet disease. Ann. Rheum. Dis. 67:1656-1662, 2008.
11. Tugal-Tutkun, I., Güney-Tefekli, E., Urgancioglu, M. Results of interferon-alfa therapy in patients with Behçet uveitis. Graefes Arch. Clin. Exp. Ophthalmol. 244:1692-1695, 2006.
12. Gueudry, J., Wechsler, B., Terrada, C., et al. Long-term efficacy and safety of low-dose interferon alpha2a therapy in severe uveitis associated with Behçet disease. Am. J. Ophthalmol. 146:837-844, 2008.
13. Imrie, F.R., and Dick, A.D. Biologics in the treatment of uveitis. Curr. Opin. Ophthalmol. 18:481-486, 2007.
14. Tsambaos, D., Eichelberg, D., and Goos, M. Behcet's syndrome: Treatment with recombinant leukocyte alphainterferon. Arch. Dermatol. Res. 278:335-336, 1986.
15. Georgiou, S., Monastirli, A., Pasmatzi, E., et al. Efficacy and safety of systemic recombinant interferon-alpha in Behçet's disease. J. Intern. Med. 243:367-372, 1998.
16. Kötter, I., Eckstein, A.K., Stübiger, N., and Zierhut, M. Treatment of ocular symptoms of Behçet's disease with interferon alpha 2a: A pilot study. Br. J. Ophthalmol. 82:488-494, 1998.
17. Krause, L., Altenburg, A., Bechrakis, N.E., et al. Intraocular surgery under systemic interferon-alpha therapy in ocular Adamantiades-Behçet's disease. Graefes Arch. Clin. Exp. Ophthalmol. 245:1617-1621, 2007.
18. Guillaume-Czitrom, S., Berger, C., Pajot, C., et al. Efficacy and safety of interferon-alpha in the treatment of corticodependent uveitis of paediatric Behcet's disease. Rheumatology 46:1570-1573, 2007.
19. Kötter, I., Zierhut, M., Eckstein, A.K., et al. Human recombinant interferon alfa-2a for the treatment of Behçet's disease with sight threatening posterior or panuveitis. Br. J. Ophthalmol. 87:423-431, 2003.
20. Bodaghi, B., Gendron, G., Wechsler, B., et al. Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: A retrospective monocentric study of 45 patients. Br. J. Ophthalmol. 91:335-339, 2007.
21. Hamuryudan, V., Ozyazgan, Y., Fresko, Y., et al. Interferon a combined with azathioprine for the uveitis of Behcet's disease: An open study. Isr. Med. Assoc. J. 4:928-930, 2002.